New Elements Pharma, Jingyin Therapeutics, and Yihoo Pharma Secure New Funding Rounds

Oct 16, 2023 22:07 CST Updated 22:07

Atom Therapeutics

Innovative Drug Developer

Sirius Therapeutics

Oligonucleotide Drug Developer

Inhal Pharma

Dry Powder Inhalation Formulations, Inhalation Devices, and Related Equipment Developer

Public data shows that in September this year (as of September 28), there were 207 financing events in the global biopharmaceutical industry. Among them,There were 25 large-scale financing events exceeding 50 million US dollars.The total amount of disclosed financing events exceeds 5.2 billion US dollars, mainly concentrated before the C round.It is worth mentioning that new technologies and R&D platform companies are gradually emerging.

Atom Therapeutics Completes Over 600 Million RMB in Series D Financing

Atom Therapeutics recently completed a Series D financing round exceeding 600 million RMB. This round was participated in by both new and existing shareholders, led by Cetus Capital, with follow-on investments from Fortune Venture Capital, Huajin Investment, Qiandao Group, and Xinyi Investment. CITIC Securities and FinCapital served as the company's financial advisors. Following this financing round, the company's total funding amounts to approximately 1.2 billion RMB. The proceeds from this Series D round will primarily be used to complete the pivotal global and China-based clinical studies of ABP-671, as well as to further advance the development of an innovative drug pipeline for treating inflammation and other diseases.

Atom Therapeutics currently has multiple products at different stages, including preclinical and clinical phases. Among them, ABP-671, a Class 1.1 innovative drug for the treatment of chronic gout, has entered pivotal clinical trials globally. ABP-671 lowers serum uric acid (sUA) levels by inhibiting the renal uric acid transporter 1 (URAT1), promoting normal excretion of urinary urate. The primary clinical endpoint is to reduce sUA to < 6 mg/dL (360 μmol/L).

Sirius Therapeutics Successfully Completes Nearly 100 Million USD Financing

Recently, Sirius Therapeutics (SHANGHAI) Co., Ltd. (referred to as "Sirius Therapeutics") announced the completion of a $60 million Series B financing round to advance the clinical development of its siRNA novel therapy pipeline and the iterative innovation of next-generation nucleic acid molecule delivery technology. This round of financing was led by H&K Capital, with participation from Prosperity Global Investment Fund. Existing investors Orbimed and Vast Rising Capital continued to increase their investments. To date, the company has raised nearly $100 million in financing.

Sirius Therapeutics is an internationally innovative biotechnology company dedicated to advancing human health and well-being. Focused on the development of next-generation nucleic acid therapies in the field of cardiovascular diseases, Sirius Therapeutics aims to become a leader in revolutionizing the prevention and treatment of chronic illnesses. Dr. Qunsheng Ji, Co-founder and CEO of Sirius Therapeutics, previously served as Vice President at WuXi AppTec and Head of the Oncology and Immunology Department. Dr. Ji brings over 20 years of experience in drug discovery and translational science. Prior to this, he worked as the Head of Bioscience at AstraZeneca's China Innovation Center.

Inhal Pharma Completes RMB 50 Million Series A Financing

Recently, Inhal Pharma, a leading innovator in dry powder inhalation (DPI) formulations in China, successfully completed its Series A financing round, raising over 50 million RMB. Since its establishment in June 2020, Ningbo Inhal Pharma Co., Ltd. has achieved significant breakthroughs in the development of DPI formulations and inhalation devices, with its valuation increasing fivefold.

This Series A round of financing was led by Beijing Saiying Capital, which focuses on the healthcare sector, with participation from multiple high-quality institutions. After this investment, Inhal Pharma plans to establish a Beijing subsidiary to advance its flagship products into the clinical stage, aiming to secure a leading position in the Chinese market. Additionally, Inhal Pharma will accelerate the development of innovative formulations and devices through collaboration with strategic partners.

Editor: Mingyao